Drug intelligence / Profile preview

SHR-6934

Development stage: Phase 1
Lead developer: Beijing Tuojie Biomedical Technology
Modality: Small Molecules
Administration: Subcutaneous

Overview

SHR-6934 is an investigational drug currently in phase 1 clinical trials. It is being developed for the treatment of heart failure. The drug is administered via subcutaneous injection, and early studies are focused on evaluating its safety, tolerability, pharmacokinetics (PK), and immunogenicity in healthy subjects. The primary sponsor for clinical development is Beijing Tuojie Biomedical Technology Co., Ltd., with involvement from Shanghai MabGen Biotech Ltd. The mechanism of action has not been disclosed publicly as of now[1][2][3][5].

Beyond the preview

Go deeper on SHR-6934.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-6934.

Explore the full profile